Posttransplant bone disease

Transplantation Reviews

Volumn 17, Issue 4, 2003, Pages 176-186

  Rix, Marianne ^a   Lewin, Ewa ^a   Olgaard, Klaus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ALUMINUM; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CLODRONIC ACID; CORTICOTROPIN; CYCLOSPORIN; ERGOCALCIFEROL; ESTROGEN; FIBROBLAST GROWTH FACTOR; GLUCOCORTICOID; GONADOTROPIN; GROWTH HORMONE; IBANDRONIC ACID; LOOP DIURETIC AGENT; MAGNESIUM; MYCOPHENOLIC ACID; OKT 3; PAMIDRONIC ACID; PARATHYROID HORMONE; PREDNISONE; RAPAMYCIN; SOMATOMEDIN; STEROID; TACROLIMUS; TESTOSTERONE; UNINDEXED DRUG; VITAMIN D;

AMENORRHEA; ANOREXIA; BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE NECROSIS; BONE REMODELING; CANCELLOUS BONE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; ENDOCRINE DISEASE; FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MORPHOMETRICS; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PHOSPHATURIA; POSTOPERATIVE COMPLICATION; REVIEW; SECONDARY HYPERPARATHYROIDISM; SECONDARY OSTEOPOROSIS; SEX DIFFERENCE; VERTEBRA FRACTURE; VITAMIN D METABOLISM; WEIGHT REDUCTION;

EID: 0344668711     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2003.08.003     Document Type: Article

References (115)

1. Grotz WH, Mundinger FA, Rasenack J, et al: Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995, 10:2096
2. Nisbeth U, Lindh E, Ljunghall S, et al: Fracture frequency after kidney transplantation. Transplant Proc 1994, 26:1764
3. Chiu MY, Sprague SM, Bruce DS, et al: Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 1998, 9:677
4. Nisbeth U, Lindh E, Ljunghall S, et al: Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999, 67:1218
5. Kasiske BL, Vazquez MA, Harmon WE, et al: Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000, 11 (Suppl):S26
6. Horber FF, Casez JP, Steiger U, et al: Changes in bone mass early after kidney transplantation. J Bone Miner Res 1994, 9:1
7. Almond MK, Kwan JT, Evans K, et al: Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 1994, 66:52
8. Rodino MA, Shane E: Osteoporosis after organ transplantation. Am J Med 1998, 104:459
9. Cayco AV, Wysolmerski J, Simpson C, et al: Posttransplant bone disease: Evidence for a high bone resorption state. Transplantation 2000, 70:1722
10. Heaf JG: Bone disease after renal transplantation. Transplantation 2003, 75:315
11. Torres A, Lorenzo V, Salido E: Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002, 13:551
12. Berthoux F, Abramowicz D, Bradley B, et al: European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.8. Bone disease. Nephrol Dial Transplant 2002, 17(Suppl):43
13. Carlini RG, Rojas E, Weisinger JR, et al: Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000, 36:160
14. Monier-Faugere MC, Mawad H, Qi Q, et al: High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000, 11: 1093
15. Dissanayake IR, Epstein S: The fate of bone after renal transplantation. Curr Opin Nephrol Hypertens 1998, 7:389
16. Caglar M, Adeera L: Factors affecting bone mineral density in renal transplant patients. Ann Nucl Med 1999, 13:141
17. Silkensen JR: Long-term complications in renal transplantation. J Am Soc Nephrol 2000, 11:582
18. Levi M: Post-transplant hypophosphatemia. Kidney Int 2001, 59:2377
19. Madsen S, Thaysen JH, Olgaard K, et al: Is renal osteodystrophy reversible? Proc Eur Dial Transplant Assoc Eur Ren Assoc 1977, 14:433
20. Rosenbaum RW, Hruska KA, Korkor A, et al: Decreased phosphate reabsorption after renal transplantation: Evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 1981, 19:568
21. Bowe AE, Finnegan R, Jan de Beur SM, et al: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001, 284:977
22. Green J, Debby H, Lederer E, et al: Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 2001, 60:1182
23. Shimada T, Mizutani S, Muto T, et al: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500
24. De Sevaux RG, Hoitsma AJ, Van Hoof HJ, et al: Abnormal vitamin D metabolism and loss of bone mass after renal transplantation. Nephron Clin Pract 2003, 93:C21
25. Lausten GS, Lemser T, Jensen PK, et al: Necrosis of the femoral head after kidney transplantation. Clin Transplant 1998, 12:572
26. Canalis E: Clinical review 83: Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996, 81:3441
27. Moe SM: The treatment of steroid-induced bone loss in transplantation. Curr Opin Nephrol Hypertens 1997, 6:544
28. Goodman GR, Dissanayake IR, Sodam BR, et al: Immunosuppressant use without bone loss-implications for bone loss after transplantation. J Bone Miner Res 2001, 16:72
29. Westeel FP, Mazouz H, Ezaitouni F, et al: Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int 2000, 58:1788
30. Cvetkovic M, Mann GN, Romero DF, et al: The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994, 57:1231
31. Inoue T, Kawamura I, Matsuo M, et al: Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. Transplantation 2000, 70:774
32. Goffin E, Devogelaer JP, Depresseux G, et al: Evaluation of bone mineral density after renal transplantation under a tacrolimus-based immunosuppression: a pilot study. Clin Nephrol 2003, 59:190
33. Goffin E, Devogelaer JP, Lalaoui A, et al: Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 2002, 15:73
34. Romero DF, Buchinsky FJ, Rucinski B, et al: Rapamycin: A bone sparing immunosuppressant? J Bone Miner Res 1995, 10:760
35. Joffe I, Katz I, Sehgal S, et al: Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats. Calcif Tissue Int 1993, 53:45
36. Dissanayake IR, Goodman GR, Bowman AR, et al: Mycophenolate mofetil: A promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 1998, 65:275
37. Julian BA, Laskow DA, Dubovsky J, et al: Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991, 325:544
38. Aroldi A, Tarantino A, Montagnino G, et al: Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study. Transplantation 1997, 63:380
39. Bryer HP, Isserow JA, Armstrong EC, et al: Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 1995, 10:132
40. Grotz WH, Mundinger FA, Gugel B, et al: Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994, 58:912
41. Ramsey-Goldman R, Dunn JE, Dunlop DD, et al: Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 1999, 14:456
42. Smets YF, van der Pijl JW, de Fijter JW, et al: Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 1998, 13:1250
43. Ball AM, Gillen DL, Sherrard D, et al: Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002, 288:3014
44. Fan SL, Almond MK, Ball E, et al: Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney Int 2000, 57:684
45. Pichette V, Bonnardeaux A, Prudhomme L, et al: Long-term bone loss in kidney transplant recipients: A cross-sectional and longitudinal study. Am J Kidney Dis 1996, 28:105
46. Mikuls TF, Julian BA, Bartolucci A, et al: Bone mineral density changes within six months of renal transplantation. Transplantation 2003, 75:49
47. Kim H, Chang K, Lee T, et al: Bone mineral density after renal transplantation. Transplant Proc 1998, 30:3029
48. Grotz WH, Mundinger FA, Gugel B, et al: Bone mineral density after kidney transplantation. A cross-sectional study in 190 graft recipients up to 20 years after transplantation. Transplantation 1995, 59:982
49. Kwan JT, Almond MK, Evans K, et al: Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab 1992, 18:166
50. Moreno A, Torregrosa JV, Pons F, et al: Bone mineral density after renal transplantation: Long-term follow-up. Transplant Proc 1999, 31:2322
51. Casez JP, Lippuner K, Horber FF, et al: Changes in bone mineral density over 18 months following kidney transplantation: The respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002, 17:1318
52. Bagni B, Gilli P, Cavallini A, et al: Continuing loss of vertebral mineral density in renal transplant recipients. Eur J Nucl Med 1994, 21:108
53. Yazawa K, Ishikawa T, Ichikawa Y, et al: Positive effects of kidney transplantation on bone mass. Transplant Proc 1998, 30:3031
54. Cueto-Manzano AM, Konel S, Hutchison AJ, et al: Bone loss in long-term renal transplantation: Histopathology and densitometry analysis. Kidney Int 1999, 55:2021
55. Yun YS, Kim BJ, Hong SP, et al: Changes of bone metabolism indices in patients receiving immunosuppressive therapy including low doses of steroids after renal transplantation. Transplant Proc 1996, 28:1561
56. Brandenburg VM, Ketteler M, Fassbender WJ, et al: Development of lumbar bone mineral density in the late course after kidney transplantation. Am J Kidney Dis 2002, 40:1066
57. Velasquez-Forero F, Mondragon A, Herrero B, et al: Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant 1996, 11 (Suppl 3):58
58. Bellorin-Font E, Rojas E, Carlini RG, et al: Bone remodeling after renal transplantation. Kidney Int 2003, 85(Suppl): 125
59. Carlini RG, Rojas E, Arminio A, et al: What are the bone lesions in patients with more than four years of a functioning renal transplant? Nephrol Dial Transplant 1998, 13(Suppl): 103
60. Adachi JD, Saag KG, Delmas PD, et al: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44:202
61. Torres A, Rodriguez AP, Concepcion MT, et al: Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998, 13(Suppl):94
62. Parker CR, Freemont AJ, Blackwell PJ, et al: Cross-sectional analysis of renal transplantation osteoporosis. J Bone Miner Res 1999, 14:1943
63. Sanchez CP, Salusky IB, Kuizon BD, et al: Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 1998, 53:1358
64. Haas M, Leko-Mohr Z, Roschger P, et al: Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003, 63:1130
65. Rojas E, Carlini RG, Clesca P, et al: The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003, 63: 1915
66. Weinstein RS, Jilka RL, Parfitt AM, et al: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274
67. Jilka RL, Weinstein RS, Bellido T, et al: Osteoblast programmed cell death (apoptosis): Modulation by growth factors and cytokines. J Bone Miner Res 1998, 13:793
68. Jilka RL, Weinstein RS, Bellido T, et al: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999, 104:439
69. Lewin E, Wang W, Olgaard K: Reversibility of experimental secondary hyperparathyroidism. Kidney Int 1997, 52:1232
70. David DS, Sakai S, Brennan BL, et al: Hypercalcemia after renal transplantation. Long-term follow-up data. N Engl J Med 1973, 289:398
71. D'Alessandro AM, Melzer JS, Pirsch JD, et al: Tertiary hyperparathyroidism after renal transplantation: Operative indications. Surgery 1989, 106:1049
72. Apaydin S, Sariyar M, Erek E, et al: Hypercalcemia and hyperparathyroidism after renal transplantation. Nephron 1999, 81:364
73. Schmid T, Muller P, Spelsberg F: Parathyroidectomy after renal transplantation: A retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997, 12:2393
74. Reinhardt W, Bartelworth H, Jockenhovel F, et al: Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998, 13:436
75. Christensen MS, Nielsen HE, Torring S: Hypercalcemia and parathyroid function after renal transplantation. Acta Med Scand 1977, 201:35
76. Parfitt AM: Hypercalcemic hyperparathyroidism following renal transplantation: Differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982, 8:92
77. Mourad M, Malaise J, Chautems RC, et al: Early posttransplant calcemia as a predictive indicator for parathyroidectomy in kidney allograft recipients with tertiary hyperparathyroidism. Transplant Proc 2000, 32:437
78. McGregor D, Burn J, Lynn K, et al: Rapid resolution of tumoral calcinosis after renal transplantation. Clin Nephrol 1999, 51:54
79. Messa P, Sindici C, Cannella G, et al: Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998, 54:1704
80. Kinnaert P, Nagy N, Decoster-Gervy C, et al: Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. World J Surg 2000, 24:1391
81. Koch Nogueira PC, David L, Cochat P: Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000, 14:342
82. Botha JF, Botha JR: Parathyroid function after successful renal transplantation. S Afr J Surg 1997, 33:113
83. McCarron DA, Muther RS, Lenfesty B, et al: Parathyroid function in persistent hyperparathyroidism: Relationship to gland size. Kidney Int 1982, 22:662
84. Kilgo MS, Pirsch JD, Warner TF, et al: Tertiary hyperparathyroidism after renal transplantation: Surgical strategy. Surgery 1998, 124:677
85. Kerby JD, Rue LW, Blair H, et al: Operative treatment of tertiary hyperparathyroidism: A single-center experience. Ann Surg 1998, 227:878
86. Krause MW, Hedinger CE: Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum Pathol 1985, 16:772
87. Matsushita H, Hara M, Endo Y, et al: Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Kidney Int 1999, 35:130
88. Loda M, Lipman J, Cukor B, et al: Nodular foci in parathyroid adenomas and hyperplasias: An immunohistochemical analysis of proliferative activity. Hum Pathol 1994, 25:1050
89. Valimaki S, Farnebo F, Forsberg L, et al: Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. Kidney Int 2001, 60:1666
90. Arnold A, Brown MF, Urena P, et al: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995, 95:2047
91. Drueke TB: Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 2000, 11:1141
92. Brossard JH, Cloutier M, Roy L, et al: Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996, 81:3923
93. Nguyen-Yamamoto L, Rousseau L, Brossard JH, et al: Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Eur J Endocrinol 2002, 147:123
94. Lepage R, Roy L, Brossard JH, et al: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998, 44:805
95. Dumoulin G, Hory B, Nguyen NU, et al: No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997, 29:746
96. Claesson K, Hellman P, Frodin L, et al: Prospective study of calcium homeostasis after renal transplantation. World J Surg 1998, 22:635
97. Uchida K, Tominaga Y, Tanaka Y, et al: Renal transplantation and secondary hyperparathyroidism. Semin Surg Oncol 1997, 13:97
98. Hemmingsen C, Staun M, Meibom K, et al: Urinary calcium excretion and renal calbindin-D28k. Kidney Blood Press Res 1997, 20:247
99. Olgaard Y, Storm T, van Wowern N, et al: Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 1992, 50:490
100. Elli A, Rivolta R, Di Palo FQ, et al: A randomized trial of deflazacort versus 6-methylprednisolone in renal transplantation - Immunosuppressive activity and side effects. Transplantation 1993, 55:209
101. Ferraris JR, Pennisi P, Pasqualini T, et al: Effects of deflazacort immunosuppression on long-term growth and growth factors after renal transplantation. Pediatr Nephrol 1997, 11:322
102. Ferraris J, Krmar R, Flores D, et al: Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. Clin Nephrol 1998, 50:172
103. Kim MS, Kim YS, Lim SK, et al: Effect of deflazacort on bone mineral density in renal transplant recipients. Transplant Proc 1998, 30:3041
104. Ferraris JR, Pasqualini T, Legal S, et al: Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrol 2000, 14:682
105. Fleisch H: Bisphosphonates: Mechanisms of action. Endocr Rev 1998, 19:80
106. Saag KG, Emkey R, Schnitzer TJ, et al: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292
107. Roux C, Oriente P, Laan R, et al: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998, 83:1128
108. Grotz W, Nagel C, Poeschel D, et al: Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001, 12:1530
109. Arlen DJ, Lambert E, Ioannidis G, et al: Treatment of established bone loss after renal transplantation with etidronate. Transplantation 2001, 71:669
110. Grotz WH, Rump LC, Niessen A, et al: Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998, 66:1004
111. Ugur A, Guvener N, Isiklar I, et al: Efficiency of preventive treatment for osteoporosis after renal transplantation. Transplant Proc 2000, 32:556
112. Reginster JY, de Froidmont C, Lecart MP, et al: Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Calcif Tissue Int 1999, 65:328
113. Ringe JD, Coster A, Meng T, et al: Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 1999, 65:337
114. De Sevaux RG, Hoitsma AJ, Corstens FH, et al: Treatment with vitamin D and calcium reduces bone loss after renal transplantation: A randomized study. J Am Soc Nephrol 2002, 13:1608
115. Giannini S, Dangel A, Carraro G, et al: Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 2001, 16:2111